Vasomotor Rhinitis

British Medical Journal (Clinical research ed.)

Volumn 294, Issue 6586, 1987, Pages 1505-1506

  Jones, A S ^a   Lancer, J M ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL ARTICLE; DIAGNOSIS; HUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; THERAPY; VASOMOTOR RHINITIS;

HUMAN; RHINITIS, VASOMOTOR;

EID: 0023182091     PISSN: 02670623     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.294.6586.1505     Document Type: Article

References (82)

1. Rundles RW. The development of allopurinol. Arch Intern Med 1985;145:1492-503.
2. Beck LH. Requiem for gouty nephropathy. Kidney Ini 1986;30:280-287.
3. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;315:1386-9.
4. Mclnnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol. Ann Rheum Dis 1981;40:245-9.
5. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
6. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82-87.
7. Dan M, Jedwab M, Peed M, Shibolet S. Allopurinol-induced toxic epidermal necrolysis. Int J Dermatol 1984;23:142-4.
8. Fong PH, Ratnagopal P, Wong KL. Drug induced toxic epidermal necrolysis. Singapore Med J 1984;25:184-6.
9. Rader R, Barnes P, Ibels L, Lunzer M, Lauer C. Fuliminant hepatic failure due to allopurinol. Aust NZ J Med 1984;14:63-65.
10. Mousson C, Justrabo E, Tantez Y, Chalopin JM, Rifle G. Hepatite et nephrite interstitielle aigues granulomateuses d'origine medicamenteuse. Nephrologie 1984;5:94-95.
11. Pennell DJ, Nunan PO, O'Doherty MJ, Croft DN. Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol. Lancet 1984;i:453.
12. Aubock J, Fritsch P. Asymptomatic hyperuricaemia and allopurinol indiced toxic epidermal necrolysis. Br Med J 1985;290:1969-1970.
13. Webster E, Panush RS. Allopurinol hypersensitivity in a patient with severe, chronic, tophaceous gout. Arthritis Rheum 1985;28:707-709.
14. Stein CM. Allopurinol hypersensitivity. S Afr Med J 1985;67:935-936.
15. Renwick IGH. Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. Br Med J 1985 291:485.
16. J 16 Worth CT, Hussein SM. Peripheral neuropathy due to long-term ingestion of allopurinol. Br Med J 1985;291:1688.
17. Ebel V, Baumann R, Czechanowski R, el al. Funf Fälle mit medikamenter- induzierten Lyell-syndrom. Innere Medizin 1985;12:280-284.
18. Vanderstigel M, Zafrani ES, Lejonc JL, Schaeffer A, Portos JL. Allopurinol hypersensitivity syndrome as a cause of hepatic fibrin ring granulomas. Gastroenterology 1986;90:188-90.
19. Guerin C, Genin C, Toulon J, Sabatier JC, Leroy G, Berthoux F. Toxicite severe de l'aHopurinol. Nephrologie 1986;7:47-49.
20. Conrad ME. Fatal aplastic anemia associated with allopurinol therapy. Am J Hematol 1986;22: 107-8.
21. Wagner P, Sweet J, Bear RA. Granulomatous interstitial nephritis associated with allopurinol therapy. Can Med Ass J 1986;135:496-7.
22. Ohsawa T, Ohtsubo M. Hepatitis associated with allopurinol. Drug Intell Clin Pharm 1986;19: 431-433.
23. Simmonds HA, Cameron JS, Morris GS, Davies PM. Allopurinol in renal failure and the tumour lysis syndrome. Clin Chim Acta 1986;160:189-95.
24. Reiter S, Simmonds HA, Webster DR, Watson AR. On the metabolism of allopurinol. Formation of allopurinol-l-riboside in purine nucleoside phosphorylase deficiency. Biochem Pharmacol 1983;32:2167-74.
25. Hande K, Reed E, Chabner B. Allopurinol kinetics. Clin Pharmacol Ther 1978;23:598-605.
26. Elion GB, Yu T-F, Gutman AB, Hitchings GH. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968;45:69-77.
27. Wood MH, Sebel E, O'Sullivan WJ. Allopurinol and thiazides. Lancet 1972;i:751.
28. Berlinger WG, Park GD, Spector R. The effect of dietary protein on the clearance of allopurinol and oxypurinol. N Engl J Med 1985;313:771-6.
29. Macias JF, Cameron JS. Renal function and renal disease in the elderly. London: Butterworths, 1987.
30. Elion GB, Benezra FM, Beardmore TD, Kelley WN. Studies with allopurinol in patients with impaired renal function. Adv Exp Med Biol 1980;122A:263-7.
31. Hayes CP, Metz EN, Robinson RR, Rundles RW. Use of allopurinol (HPP) to control hyperuricemia in patients on chronic intermittent dialysis. Trans Am Soc Artif Intern Organs 1965;11:247-51.
32. Cockcroft D, Gault MK. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
33. Gibson T, Simmonds HA, Rodgers AV, et al. Gout with apparent resistance to allopurinol. Ann Rheum Dis 1983;42:93-95.
34. Hande KR, Hixson CV, Chabner BA. Postchemistry purine excretion in lymphoma patients receiving allopurinol. Cancer Res 1981;41:2273-9.
35. Greene ML, Fujimoto WY, Seegmiller JM. Urinary xanthine stone. A rare complication of allopurinol therapy. N Engl J Med 1969;280:426-7.
36. Band PR, Silverberg DS, Henderson JF, et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970;283:354-357.
37. Mizuno T, Segawa M, Kurumada T, et al. Clinical and theraputic aspects of the Lesch-Nyhan syndrome in Japanese children. Neuropadiatrie 1970;2:38-52.
38. Manzke H, Harms D, Dorner K. Zur Problematik der Behandlung der kongenitalen Hyperurikämie. Monatschrift für Kinderheilkunde 1971;119:424-8.
39. Ablin A, Stephens BG, Nirata T, et al. Nephropathy, xanthinuria and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Metabolism 1972;21:771-8.
40. Gomez GA, Stutzman L, Chu TM. Xanthine nephropathy during chemotherapy in deficiency of hypoxanthine-guanine phosphoribosyltransferase. Arch Intern Med 1978;138:1017-9.
41. Sperling O, Brosh S, Boer P, et al. Urinary xanthine stones in an allopurinol-treated gouty patient with partial deficiency of hypoxanthine-guanine phosphoribosyltransferase. Isr J Med Sci 1978;14:288-92.
42. Brock WA, Golden J, Kaplan GW. Xanthine calculi in the Lesch-Nyhan syndrome. J Urol 1983;130:157-9.
43. Ogawa A, Watanabe K, Minejima N. Renal xanthine stone in Lesch-Nyhan syndrome treated with allopurinol. Urology 1985;26:56-58.
44. Oka T, Utsonomiya M, Ichikawa Y, et al. Xanthine calculi in the patient with the Lesch-Nyhan syndrome associated with urinary tract infection. Urol Int 1985;40:138-40.
45. Gibson T, Highton J, Potter C, Simmonds HA. Renal impairment and gout. Ann Rheum Dis 1980;39:417-23.
46. Simmonds HA, Warren DJ, Cameron JS, Potter CF, Farebrother DA. Familial gout and renal failure in young women. Clin Nephrol 1980;14:176-182.
47. Rosenfeld JB. Effect of long-term allopurinol administration on serum creatinine and GFR in normotensive and hypertensive hyperuricemia subjects. Adv Exp Biol Med 1974;41B:581-96.
48. Mygind N, Dirksen A, Johnsen NJ, Weeke B. Perennial rhinitis: an analysis of skin testing, serum IgE, and blood and smear eosinophilia in 201 patients. Clin Otolaryngol 1978;3:189-96.
49. Mullarkey MF, Hill JS, Webb DR. Allergic and non-allergic rhinitis: their characterisation with attention to the meaning of nasal eosinophilia. J Allergy Clin Immunol 1980;65:122-6.
50. Mygind N. Nasal allergy. Oxford: Blackwell Scientific Publications, 1978:231.
51. Mygind N, Weeke B. Allergic and non-allergic rhinitis. In: Middleton E Jr, Reed CE, Ellis EF, eds. Allergy: principles and practice. Saint Louis: CV Mosby, 1983:1101-17.
52. Wentges R.T.H.R. Allergic and vasomotor rhinitis. In: Maran AGD, Stell PM, eds. Clinical Otolaryngology. Oxford: Blackwell Scientific Publications, 1979:226-238.
53. Malcolmson KG. The vasomotor activities of the nasal mucous membrane. J Laryngol Otol 1959;73:73-98.
54. Borum P, Mygind N, Schultz Larsen F. Intranasal ipratropium: a new treatment for perennial rhinitis. Clin Otolaryngol 1979;4:4078-5011.
55. Moore DC. Stellate ganglion block. Springfield, Charles C Thomas, 1954:42-3.
56. Malm L. Stimulation of sympathetic nerve fibres to the nose in cats. Acta Otolaryngol (Stockh) 1973;75:519-26.
57. Malm L. Responses of resistance and capacitance vessels in feline nasal mucosa to vasoactive agents. Acta Otolaryngol (Stockh) 1974;78:90-97.
58. Gorenberg D. Rhinitis medicamentosa. West J Med 1979;131:313-4.
59. Malm L. Propranolol as cause of watery nasal secretion. Lancet 1981; i: 1006.
60. Jackson RT, Rooker DW. Stimulation and secretion of the Vidian nerve in relation to autonomic control of the nasal vasculature. Laryngoscope 1971;81:565-9.
61. Ecdes R, Wilson H. The parasympathetic secretory nerves of the nose of the cat. J Physiol 1973;230:213-23.
62. Golding-Wood PH. Vidian neurectomy: its results and complications. Laryngoscope 1973;83: 1673-83.
63. Bedwani JR, Ecdes R, Jones AS. Effects of prostaglandins E2,12 and D2 on pig nasal vasculature. Clin Otolaryngol 1983;8:337-41.
64. Anggard A. The effect of prostaglandins on nasal airway resistance in man. Ann Otol Rhinol Laryngol 1969;78:657-62.
65. Jones AS, Lancer JM, Moir AA, Stevens JC. Effect of aspirin on nasal resistance to airflow. Br Med J 1985;290:1171-3.
66. Settipane GA, Chafee FH. Nasal polyps in asthma and rhinitis; a review of6037 patients. J Allergy Clin Immunol 1977;59:17-21.
67. Caplin I, Haynes JT, Spahn J. Are nasal polyps an allergic phenomenon? Ann Allergy 1971; 29: 631-4.
68. Broms P, Malm L. Oral vasoconstrictors in perennial non-allergic rhinitis. Allergy 1982;37:67-74.
69. Bentley AJ, Jackson RT. Changes in the patency of the upper nasal passage induced by histamine and anti-histamines. Laryngoscope 1970;80:1859-1870.
70. Axelsson A, Hammer G. Treatment of vasomotor rhinitis with a combined antihistamine-sympathomimetic preparation. Acta Allergol 1971;26:357-62.
71. Anggard A, Malm L. Orally administered decongestant drugs in disorders of the upper respiratory passages: A survey of clinical results. Clin Otolaryngol 1984;9:43-49.
72. Proctor DF, Adams GK. Physiology and pharmacology of nasal function and mucus secretion. Pharmacol Ther4. 1976;2:493-509.
73. Capel LH, Swanston AR. Beware congesting nasal decongestants. Br Med J 1986;293:1258-9.
74. Aschan G, Drettner B. An objective investigation of the decongestive effect of xylometazoline. Eye Ear Nose and Throat Monthly 1964;43:66-74.
75. Toohill RJ, Lehman RH, Grossman TW, Belson TP. Rhinitis medicamentosa. Laryngoscope 1981;91:1614-21.
76. Brown HM, Storey G, George WHS. Bedomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J 1972;i:585-90.
77. Pipkorn U, Rundcrantz H, Lindqvist S, Lindqvist N. Budesonide—a new nasal steroid. Rhinology 1980;18:171-5.
78. Mygind N, Brahe Pedersen C, Prytz S, Sorensen H. Treatment of nasal polyps with intranasal bedomethasone dipropionate aerosol. Clin Allergy 1975;5:159-64.
79. Drettner B, Ebbesen A, Nilsson M. Prophylactic treatment with flunisolide after polypectomy. Rhinology 1982;20:149-58.
80. Jones AS, Lancer JM. Does submucosal diathermy to the inferior turbinates reduce nasal resistance to airflow in the long term? J Laryngol Otol 1987;101:448-50.
81. Ophir D, Shapira A, Marshak G. Total inferior turbinectomy for nasal airway obstruction. Arch Otolaryngol 1985;111:93-5.
82. Minnis NL, Morrison AW. Trans-septal approach for Vidian neurectomy. J Laryngol Otol 1971;85:255-60.